Xeris Biopharma Holdings, Inc. (XERS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$13.08+25.05%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · XERS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -4.3% |
| Our one-year growth estimate | diamond | 36.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 40.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
XERS — director transition
Dated 2026-11-02
Director — Menassie Taddese: The filing discloses the appointment of a new independent director to fill a board vacancy, which is a routine governance action and not an executive departure.
Why it matters: The August report raised the full-year range. Q3 results will show whether sales stay on that path.
Supportive ifQ3 total revenue is at least $92.1 million, and management keeps its $385M–$390M full-year guide.
Worry ifQ3 total revenue is below $92.1 million, or management cuts its full-year guide to below $385 million.
Why it matters: The new patent could protect Keveyis for longer. The notice is not yet a granted patent.
Supportive ifThe USPTO grants the allowed Keveyis patent, with protection stated to last through at least 2039.
Worry ifThe USPTO rejects the application or the granted patent does not protect Keveyis through 2039.
Why it matters: Recorlev drove most recent sales growth. Slower growth could weaken the full-year revenue path.
Supportive ifQ3 Recorlev net revenue grows at least 50% year over year from $31.4 million.
Worry ifQ3 Recorlev net revenue grows less than 25% year over year from $31.4 million.
Why it matters: Adjusted EBITDA rose in Q2, while the company still posted a GAAP net loss. Another gain would support improving operating results.
Supportive ifQ3 adjusted EBITDA is above $19.3 million, the Q2 2026 result.
Worry ifQ3 adjusted EBITDA is below $15.1 million, the Q1 2026 result.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$160 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $456 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,657 loss on $10,000 · 46.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The trial is the next major step for Xeris's lead drug candidate. A delay would push back its development plan.
Supportive ifXeris says Cornerstone has started by December 31, 2026.
Worry ifXeris reports that Cornerstone has not started by December 31, 2026, or delays its start.